Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ryan Sobel"'
Autor:
Junko Yano, Jack D. Sobel, Paul Nyirjesy, Ryan Sobel, Valerie L. Williams, Qingzhao Yu, Mairi C. Noverr, Paul L. Fidel
Publikováno v:
BMC Women's Health, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Vulvovaginal candidiasis (VVC) is a common infection affecting women worldwide. Reports of patterns/risk factors/trends for episodic/recurrent VVC (RVVC) are largely outdated. The purpose of this study was to obtain current patien
Externí odkaz:
https://doaj.org/article/f264f5be5dcb486abc7ec990dbdd3471
Autor:
Mariel Becker, Ryan Sobel
Publikováno v:
Current Infectious Disease Reports. 25:61-66
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f0a02a6342c80af1a028230d3a54ecc
https://doi.org/10.1007/s11908-023-00801-z
https://doi.org/10.1007/s11908-023-00801-z
Publikováno v:
Journal of Lower Genital Tract Disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7dd555b05e28a3b332fc178cb697c40
https://doi.org/10.1097/lgt.0000000000000733
https://doi.org/10.1097/lgt.0000000000000733
Autor:
Jack D. Sobel, Ryan Sobel, Paul Nyirjesy, Nkechi Azie, Dimitar A Delchev, Mahmoud A. Ghannoum, Itzel A Harriott, David Angulo, Katyna Borroto-Esoda
Publikováno v:
BJOG: An International Journal of Obstetrics & Gynaecology. 129:412-420
OBJECTIVE To evaluate the efficacy and safety of ibrexafungerp versus placebo for acute vulvovaginal candidiasis (VVC) treatment. DESIGN Global phase 3, randomised, placebo-controlled superiority study. SETTING Study sites in the USA (n = 19) and Bul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b69991ad7a8c945f6552a1983b3e081
https://doi.org/10.1111/1471-0528.16972
https://doi.org/10.1111/1471-0528.16972
Autor:
Samuel N. Lederman, Nkechi Azie, Itzel A Harriott, Paul Nyirjesy, Alfred H. Moffett, Steven A Sussman, David L Weinstein, David Angulo, Mahmoud A. Ghannoum, Mark Jacobs, Janet K Gersten, B Todd Chappell, Jack D. Sobel, Katyna Borroto-Esoda, Jane R. Schwebke, Ryan Sobel
Publikováno v:
Clinical Infectious Diseases. 74:1979-1985
Background Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity. The objective of this study was to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea13bf4874f59720e6c2b9f704141393
https://doi.org/10.1093/cid/ciab750
https://doi.org/10.1093/cid/ciab750
Autor:
Oluwatosin Goje, Ryan Sobel, Paul Nyirjesy, Steven R. Goldstein, Mark Spitzer, Brooke Faught, Shelagh Larson, Thomas King, Nkechi E. Azie, David Angulo, Jack D. Sobel
Publikováno v:
Journal of women's health (2002).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e35bcef87645365d24b5bf936aeb9e94
https://pubmed.ncbi.nlm.nih.gov/36255448
https://pubmed.ncbi.nlm.nih.gov/36255448
Autor:
Paul Nyirjesy, Jack D. Sobel, Junko Yano, Valerie Williams, Qingzhao Yu, Paul L. Fidel, Mairi C. Noverr, Ryan Sobel
Publikováno v:
BMC Women's Health, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Women's Health
BMC Women's Health
Background Vulvovaginal candidiasis (VVC) is a common infection affecting women worldwide. Reports of patterns/risk factors/trends for episodic/recurrent VVC (RVVC) are largely outdated. The purpose of this study was to obtain current patient perspec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2661839d7ce2d92b7f518be79f74be
http://link.springer.com/article/10.1186/s12905-019-0748-8
http://link.springer.com/article/10.1186/s12905-019-0748-8
Autor:
Jack D. Sobel, Ryan Sobel
Publikováno v:
Expert opinion on pharmacotherapy. 22(12)
Given the frequency of recurrent bacterial vaginosis (RBV), enhancing treatment and preventing recurrence have become the central target of pharmacotherapy today. Antimicrobial failure is occurring at a time when knowledge of pathogenesis of bacteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25bed1814a1e3d03805bcd98b4d8067a
https://pubmed.ncbi.nlm.nih.gov/33750246
https://pubmed.ncbi.nlm.nih.gov/33750246
Autor:
Ryan Sobel, Kannika Story
Publikováno v:
Current Infectious Disease Reports. 22
Due to broad spectrum susceptibility of Candida species to fluconazole, its convenience as an oral agent, and predictable patient tolerance and safety, current practice guidelines recommend the use of long-term suppression regimens of fluconazole as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1626fb62705d934c136b36f73a8e223b
https://doi.org/10.1007/s11908-020-0712-7
https://doi.org/10.1007/s11908-020-0712-7
Autor:
Jack D. Sobel, Ryan Sobel
Publikováno v:
Expert Opinion on Pharmacotherapy. 19:971-977
Clinicians are increasingly challenged by patients with refractory vulvovaginal candidiasis (VVC) caused by azole-resistant Candida species. Fluconazole resistant C.albicans is a growing and perplexing problem following years of indiscriminate drug p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cca87bea262a077273dd5e06afd1eec
https://doi.org/10.1080/14656566.2018.1476490
https://doi.org/10.1080/14656566.2018.1476490